Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

What are called autoimmune diseases can affect just about every part of the body — and tens of millions of people. While most ...

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's ...

Aging and shifting hormone levels influence how MS changes over time, and the overlap of these factors during midlife can ...

After 30 years of living with Multiple Sclerosis (MS), country music star Clay Walker shared that the disease has recently ...

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...